Tags

Type your tag names separated by a space and hit enter

Liquid chromatography - tandem mass spectrometry for the simultaneous quantitation of glipizide, cilostazol and its active metabolite 3, 4-dehydro-cilostazol in rat plasma: application for a pharmacokinetic study.
Arzneimittelforschung. 2012 Sep; 62(9):425-32.A

Abstract

A liquid chromatography-electrospray ionization tandem mass spectrometry (HPLC-ESI-MS/MS) method for the simultaneous quantitation of glipizide, cilostazol and 3, 4-dehydro-cilostazol in rat plasma was developed and validated. Glimepride was used as an internal standard (IS). The analytes were extracted by using liquid-liquid extraction procedure and separated on a reverse phase C18 column (50 mm×4.6 mm i. d., 5 µ) using acetonitrile: 2 mM ammonium acetate buffer, pH 3.2 (90:10, v/v) as mobile phase at a flow rate 0.4 mL/min in an isocratic mode. Selective reaction monitoring was performed using the transitions m/z 446.4>321.1, 370.2>288.3, 368.3>286.2, and 491.4>352.2 to quantify glipizide, cilostazol, 3, 4-dehydro-cilostazol and glimepride, respectively. Calibration curves were constructed over the range of 25-2 000 ng/mL for glipizide, cilostazol and 3, 4-dehydro-cilostazol. The lower limit of quantitation was 25 ng/mL for all the analytes. The recoveries from spiked control samples were>76% for all analytes and internal standard. Intra and inter day accuracy and precision of validated method were within the acceptable limits of at all concentration. The quantitation method was successfully applied for simultaneous estimation of glipizide, cilostazol and 3, 4-dehydro-cilostazol in a pharmacokinetic drug-drug interaction study in wistar rats.

Authors+Show Affiliations

Incozen Therapeutics Private Limited, Andhra Pradesh, India. satheesh.trs@gmail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22821721

Citation

Satheeshmanikandan, T R S., et al. "Liquid Chromatography - Tandem Mass Spectrometry for the Simultaneous Quantitation of Glipizide, Cilostazol and Its Active Metabolite 3, 4-dehydro-cilostazol in Rat Plasma: Application for a Pharmacokinetic Study." Arzneimittel-Forschung, vol. 62, no. 9, 2012, pp. 425-32.
Satheeshmanikandan TR, Sridhar V, Kanthikiran VV, et al. Liquid chromatography - tandem mass spectrometry for the simultaneous quantitation of glipizide, cilostazol and its active metabolite 3, 4-dehydro-cilostazol in rat plasma: application for a pharmacokinetic study. Arzneimittelforschung. 2012;62(9):425-32.
Satheeshmanikandan, T. R., Sridhar, V., Kanthikiran, V. V., Swaroopkumar, V. V., & Mukkanti, K. (2012). Liquid chromatography - tandem mass spectrometry for the simultaneous quantitation of glipizide, cilostazol and its active metabolite 3, 4-dehydro-cilostazol in rat plasma: application for a pharmacokinetic study. Arzneimittel-Forschung, 62(9), 425-32. https://doi.org/10.1055/s-0032-1316374
Satheeshmanikandan TR, et al. Liquid Chromatography - Tandem Mass Spectrometry for the Simultaneous Quantitation of Glipizide, Cilostazol and Its Active Metabolite 3, 4-dehydro-cilostazol in Rat Plasma: Application for a Pharmacokinetic Study. Arzneimittelforschung. 2012;62(9):425-32. PubMed PMID: 22821721.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Liquid chromatography - tandem mass spectrometry for the simultaneous quantitation of glipizide, cilostazol and its active metabolite 3, 4-dehydro-cilostazol in rat plasma: application for a pharmacokinetic study. AU - Satheeshmanikandan,T R S, AU - Sridhar,V, AU - Kanthikiran,V V S, AU - Swaroopkumar,V V S, AU - Mukkanti,K, Y1 - 2012/07/20/ PY - 2012/7/24/entrez PY - 2012/7/24/pubmed PY - 2012/11/14/medline SP - 425 EP - 32 JF - Arzneimittel-Forschung JO - Arzneimittelforschung VL - 62 IS - 9 N2 - A liquid chromatography-electrospray ionization tandem mass spectrometry (HPLC-ESI-MS/MS) method for the simultaneous quantitation of glipizide, cilostazol and 3, 4-dehydro-cilostazol in rat plasma was developed and validated. Glimepride was used as an internal standard (IS). The analytes were extracted by using liquid-liquid extraction procedure and separated on a reverse phase C18 column (50 mm×4.6 mm i. d., 5 µ) using acetonitrile: 2 mM ammonium acetate buffer, pH 3.2 (90:10, v/v) as mobile phase at a flow rate 0.4 mL/min in an isocratic mode. Selective reaction monitoring was performed using the transitions m/z 446.4>321.1, 370.2>288.3, 368.3>286.2, and 491.4>352.2 to quantify glipizide, cilostazol, 3, 4-dehydro-cilostazol and glimepride, respectively. Calibration curves were constructed over the range of 25-2 000 ng/mL for glipizide, cilostazol and 3, 4-dehydro-cilostazol. The lower limit of quantitation was 25 ng/mL for all the analytes. The recoveries from spiked control samples were>76% for all analytes and internal standard. Intra and inter day accuracy and precision of validated method were within the acceptable limits of at all concentration. The quantitation method was successfully applied for simultaneous estimation of glipizide, cilostazol and 3, 4-dehydro-cilostazol in a pharmacokinetic drug-drug interaction study in wistar rats. SN - 0004-4172 UR - https://www.unboundmedicine.com/medline/citation/22821721/Liquid_chromatography___tandem_mass_spectrometry_for_the_simultaneous_quantitation_of_glipizide_cilostazol_and_its_active_metabolite_3_4_dehydro_cilostazol_in_rat_plasma:_application_for_a_pharmacokinetic_study_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-0032-1316374 DB - PRIME DP - Unbound Medicine ER -